Trials / Completed
CompletedNCT04542135
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Alison Stopeck · Academic / Other
- Sex
- Female
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sulindac Pill | Randomized participants will receive either 150 mg oral sulindac twice daily. |
| DRUG | Placebo | placebo pills twice daily |
Timeline
- Start date
- 2020-11-20
- Primary completion
- 2025-04-22
- Completion
- 2025-05-19
- First posted
- 2020-09-09
- Last updated
- 2025-06-03
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04542135. Inclusion in this directory is not an endorsement.